LEO Pharma
Industriparken 55
DK-2750 Ballerup
Copenhagen
Tel: 45-4492-3800
Fax: 45-4494-3040
Website: http://www.leo-pharma.com/
Email: leo.group@leo-pharma.com
137 articles with LEO Pharma
-
LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology
3/10/2023
LEO Pharma and ICON plc announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.
-
Health Canada approves ADTRALZA (tralokinumab) for the treatment of adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis
2/8/2023
LEO Pharma Inc. today announced the Health Canada approval of Adtralza® (tralokinumab) for adolescent patients aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
-
LEO Pharma Announces British Journal of Dermatology Publication of Adbry™ (tralokinumab-ldrm) Pooled Safety Data in Moderate-to-Severe Atopic Dermatitis
10/26/2022
LEO Pharma Inc. announced that the British Journal of Dermatology published detailed results from a pooled safety analysis of Adbry™ from three pivotal Phase 3 trials, Phase 2 and Phase 2b trials of adult patients with moderate-to-severe atopic dermatitis.
-
LEO Pharma Announces European Commission Approval of Adtralza® (tralokinumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents
10/20/2022
LEO Pharma Announces European Commission Approval of Adtralza ® (tralokinumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents.
-
LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adolescents With Moderate-to-Severe Atopic Dermatitis
9/16/2022
LEO Pharma A/S, a global leader in medical dermatology, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending to extend the approval of Adtralza® (tralokinumab) in the European Union (EU) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.
-
LEO Pharma presents new AdbryTM (tralokinumab-ldrm) safety data in moderate-to-severe atopic dermatitis at 31st EADV Congress
9/8/2022
LEO Pharma A/S, a global leader in medical dermatology, today announced new safety data for AdbryTM (tralokinumab-ldrm) for adult patients with moderate-to-severe atopic dermatitis (AD).
-
LEO Pharma Announces Publication of Adbry™ (tralokinumab-ldrm) Efficacy Data in Moderate-to-Severe Atopic Dermatitis in American Journal of Clinical Dermatology
7/20/2022
LEO Pharma A/S, a global leader in medical dermatology, today announced that American Journal of Clinical Dermatology published 32-week results from a post-hoc analysis of the Phase 3 ECZTRA 3 clinical trial (NCT03363854) in atopic dermatitis (AD).
-
Vipergen and LEO Pharma Partner for DNA Encoded Library (DEL)-Based Drug Discovery for Dermatology Indications
6/15/2022
Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library technologies, announced a multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications.
-
LEO Pharma Presents New Interim Long-Term Efficacy Data for Adbry™ (tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 RAD Conference
4/11/2022
LEO Pharma A/S, a global leader in medical dermatology, today announced 3-year data that help provide insight into the long-term efficacy profile of Adbry™ (tralokinumab-ldrm) in adult patients with moderate-to-severe atopic dermatitis (AD).
-
Sequence Bio announces Discovery Collaboration Agreement with LEO Pharma
4/7/2022
Sequence Bio announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio's proprietary discovery platform to identify novel dermatologic drug targets.
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
LEO Pharma Presents New Interim Long-Term Safety and Efficacy Data for Adbry™ (tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 AAD Annual Meeting
3/25/2022
LEO Pharma A/S today announced up to 3.5-year data that further support the long-term safety and efficacy profile of Adbry™ (tralokinumab-ldrm) in adult patients with moderate-to-severe atopic dermatitis (AD). Interim results were shared as a poster presentation at the American Academy of Dermatology (AAD) 2022 Annual Meeting.
-
LEO Pharma A/S Appoints Brian Hilberdink New President of LEO Pharma Inc. United States
2/17/2022
LEO Pharma A/S today announced it has appointed Brian Hilberdink new Executive Vice President and President of LEO Pharma Inc. in the United States, effective March 14, 2022.
-
This week, two biotechnology firms announced new leadership, David Nassif, J.D., and Christophe Bourdon.
-
LEO Pharma announces FDA approval of Adbry™ (tralokinumab-ldrm) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis
12/28/2021
LEO Pharma Inc. announced that the U.S. Food and Drug Administration has approved Adbry™ for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
-
The decision to allow the release of Adbry follows positive results from the Phase III ECZTRA trials, which covered almost 2,000 patients living with moderate to severe atopic dermatitis.
-
Genoskin’s solution is to develop the technologies to replace animals and humans in clinical studies with virtual models, steadily pushing living creatures further and further from testing.
-
Tralokinumab Achieves Primary and Secondary Endpoints in Phase 3 Trial of Adolescents With Moderate-to-Severe Atopic Dermatitis
10/22/2021
LEO Pharma A/S today announced 16-week results of a 52-week monotherapy trial showing tralokinumab significantly improved primary and secondary measurements of efficacy among adolescents (aged 12 to 17) with moderate-to-severe atopic dermatitis.
-
Skin health logged major wins this week after two companies announced positive clinical trial results.
-
The Product Monograph for Protopic® has been updated
10/4/2021
LEO Pharma Inc. announced that Health Canada has approved an update to the Product Monograph of Protopic®, removing the Serious Warnings and Precautions box, also referred to as a boxed warning, regarding a potential association with the use of topical calcineurin inhibitors and malignancy.